Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Cancer

Explore clinical trials studying Fallopian Tube Cancer. Study availability and eligibility vary by location and protocol.

330 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Cancer trial results

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Conditions
Acinar Cell Carcinoma, Adenocarcinoma, Adnexal Diseases, +55 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic (Arizona) Scottsdale, Arizona, United States
  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute Little Rock, Arkansas, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 82 locations
View Trial Details
Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations
  • University of Alabama at Birmingham (UAB) Hospital /ID# 274793 Birmingham, Alabama, United States
  • Usa Mitchell Cancer Institute /ID# 276022 Mobile, Alabama, United States
  • University of California Los Angeles Medical Center /ID# 274566 Los Angeles, California, United States
  • Scripps Md Anderson - Prebys Cancer Center /ID# 276891 San Diego, California, United States
View all 67 locations
View Trial Details
Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumors, +35 more
Locations
  • Sarah Cannon Research Institute (SCRI) - Lake Nona Orlando, Florida, United States
  • Emory Winship Cancer Institute Atlanta, Georgia, United States
  • University Medical Center of New Orleans LSU-LCMC Health Cancer Center New Orleans, Louisiana, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 17 locations
View Trial Details
Recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

NCT05460000

Conditions
Adenocarcinoma, Adenocarcinoma, Clear Cell, Adnexal Diseases, +23 more
Locations
  • Universitätsklinik Innsbruck Innsbruck, Austria
  • Cliniques Universitaires St. Luc Brussels, Belgium
  • UZ Gent Ghent, Belgium
  • Jessa ziekenhuis Hasselt, Belgium
View all 50 locations
View Trial Details
Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • University of Alabama at Birmingham ( Site 0006) Birmingham, Alabama, United States
  • Alaska Women's Cancer Care ( Site 0096) Anchorage, Alaska, United States
  • UCSF Medical Center at Mission Bay ( Site 0013) San Francisco, California, United States
  • John Muir Health Cancer Center ( Site 0016) Walnut Creek, California, United States
View all 186 locations
View Trial Details
Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +25 more
Locations
  • 004 Birmingham, Alabama, United States
  • 150 Palo Alto, California, United States
  • 014 San Francisco, California, United States
  • 544 Fort Myers, Florida, United States
View all 49 locations
View Trial Details
Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations
  • Advent Health Orlando, Florida, United States
  • Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States
  • Washington University School of Medicine in St. Louis St Louis, Missouri, United States
  • Providence Cancer Institute Portland, Oregon, United States
View Trial Details
Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • City of Hope Lennar Irvine, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Northwestern Memorial Hospital Chicago, Illinois, United States
  • University of Pennsylvania Health System, Perelman Center for Advanced Medicine Philadelphia, Pennsylvania, United States
View Trial Details
Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Conditions
Adnexal Diseases, DNA Virus Infections, Endocrine Gland Neoplasms, +26 more
Locations
  • The University of South Alabama, Mitchell Cancer Institute Mobile, Alabama, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health - Moores Cancer Center La Jolla, California, United States
View all 32 locations
View Trial Details

Related conditions